SEC Form 4 · accession 0001209191-16-121364
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frederick W Driscoll
Officer — Chief Financial Officer
Period of report
May 17, 2016
Accepted (ET)
May 18, 2016 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 17, 2016 | P | 2,500 | $9.8672 | A | 8,434 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The weighted average purchase price for the transaction reported was $9.86720, and the range of prices were between $9.72 and $10.029. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.